Addrenex makes appointments
This article was originally published in Scrip
Addrenex Pharmaceuticals, a two-year-old US firm, has appointed Steven Butts vice-president of commercial affairs, Dr Gary Bream senior director of scientific affairs, and Yuki Prescott clinical trials manager. Mr Butts has worked at Biobehavioral Diagnostics and Lilly, while Dr Bream and Ms Prescott most recently served at Constella. Addrenex has filed a sustained-release clonidine product, CloniBID, for US approval in hypertension, and has an extended-release clonidine, Clonicel, in Phase III trials for attention deficit hyperactivity disorder; both products will be marketed by licensee Sciele Pharma.